Guangdong VTR Bio-Tech Co., Ltd. (300381.SZ)
CNY 8.04
(1.9%)
CNY 8.04
(1.9%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.00 CNY | -100.0% |
| 2022 | 51.31 Million CNY | -59.57% |
| 2021 | 126.92 Million CNY | 6.6% |
| 2020 | 119.07 Million CNY | -75.51% |
| 2019 | 486.25 Million CNY | -33.08% |
| 2018 | 726.63 Million CNY | 397.69% |
| 2017 | 146 Million CNY | -28.95% |
| 2016 | 205.5 Million CNY | 28.04% |
| 2015 | 160.5 Million CNY | 79.33% |
| 2014 | 89.5 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 300 Thousand CNY | -62.5% |
| 2008 | 800 Thousand CNY | -27.27% |
| 2007 | 1.1 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | -49.74 Million CNY | 0.0% |
| 2024 Q3 | 8.63 Million CNY | 0.0% |
| 2024 Q1 | 2.00 CNY | -100.0% |
| 2023 FY | 1.00 CNY | -100.0% |
| 2023 Q4 | 1.00 CNY | -100.0% |
| 2023 Q2 | 51.92 Million CNY | 0.6% |
| 2023 Q1 | 51.61 Million CNY | 0.58% |
| 2023 Q3 | 52.24 Million CNY | 0.62% |
| 2022 Q3 | 50.95 Million CNY | 0.66% |
| 2022 Q2 | 50.61 Million CNY | 0.61% |
| 2022 Q1 | 50.31 Million CNY | -60.36% |
| 2022 FY | 51.31 Million CNY | -59.57% |
| 2022 Q4 | 51.31 Million CNY | 0.72% |
| 2021 Q3 | 187.62 Million CNY | -7.25% |
| 2021 Q2 | 202.28 Million CNY | 6.04% |
| 2021 Q1 | 190.77 Million CNY | 60.22% |
| 2021 FY | 126.92 Million CNY | 6.6% |
| 2021 Q4 | 126.92 Million CNY | -32.35% |
| 2020 Q3 | 113.51 Million CNY | -21.72% |
| 2020 Q1 | 373.47 Million CNY | -23.19% |
| 2020 FY | 119.07 Million CNY | -75.51% |
| 2020 Q2 | 145 Million CNY | -61.17% |
| 2020 Q4 | 119.07 Million CNY | 4.9% |
| 2019 FY | 486.25 Million CNY | -33.08% |
| 2019 Q1 | 727.82 Million CNY | 0.16% |
| 2019 Q2 | 681.29 Million CNY | -6.39% |
| 2019 Q4 | 486.25 Million CNY | -9.94% |
| 2019 Q3 | 539.91 Million CNY | -20.75% |
| 2018 Q2 | 219.5 Million CNY | -10.77% |
| 2018 Q3 | 222.5 Million CNY | 1.37% |
| 2018 FY | 726.63 Million CNY | 397.69% |
| 2018 Q4 | 726.63 Million CNY | 226.58% |
| 2018 Q1 | 246 Million CNY | 68.49% |
| 2017 Q4 | 146 Million CNY | -15.36% |
| 2017 Q2 | 207.5 Million CNY | 0.97% |
| 2017 Q1 | 205.5 Million CNY | 0.0% |
| 2017 FY | 146 Million CNY | -28.95% |
| 2017 Q3 | 172.5 Million CNY | -16.87% |
| 2016 Q3 | 247 Million CNY | 0.0% |
| 2016 Q2 | 247 Million CNY | 53.89% |
| 2016 FY | 205.5 Million CNY | 28.04% |
| 2016 Q1 | 160.5 Million CNY | 0.0% |
| 2016 Q4 | 205.5 Million CNY | -16.8% |
| 2015 Q2 | 89 Million CNY | -0.56% |
| 2015 FY | 160.5 Million CNY | 79.33% |
| 2015 Q4 | 160.5 Million CNY | 80.34% |
| 2015 Q3 | 89 Million CNY | 0.0% |
| 2015 Q1 | 89.5 Million CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 89.5 Million CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 FY | 89.5 Million CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 Q3 | - CNY | 0.0% |
| 2010 FY | - CNY | -100.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2009 FY | 300 Thousand CNY | -62.5% |
| 2008 FY | 800 Thousand CNY | -27.27% |
| 2007 FY | 1.1 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Lifecome Biochemistry Co.,Ltd. | 527 Million CNY | 100.0% |
| Chengdu Kanghua Biological Products Co., Ltd. | -6.19 Million CNY | 100.0% |
| NanHua Bio-medicine Co., Ltd | 13 Million CNY | 100.0% |
| Shandong Sito Bio-technology Co., Ltd. | 115.59 Million CNY | 100.0% |
| Porton Pharma Solutions Ltd. | 1.07 Billion CNY | 100.0% |
| Zhejiang Wecome Pharmaceutical Company Limited | 163.13 Million CNY | 100.0% |